| 摘要 |
The present invention relates to a novel engineered receptor CD4 which is designated CD4-GP41c and, when expressed with CXCR4 or CCR5 at the surface of a gene therapy retrovirus allows a more efficient and specific infection of HIV infected cells than CD4. The present invention also relates to a method of producing said novel retrovirus vectors. The present invention also relates to recombinant viruses expressing membrane proteins CD4-GP41c or CD4-GP41c/DC-SIGNs, or expressing membrane proteins CD4/DC-SIGN, with either one of its co-receptors CXCR4 or CCR5 allowing the delivery of a gene of interest, for targeting and delivering said gene of interest specifically to virus-infected cells, particularly HIV+ infected cell, and thereby triggering cell death. The recombinant virus according to the present invention is particular useful as a gene therapy vector, as it confers efficient and specific gene transfer to virus-infected cells, such as HIV- infected T helper cells and macrophages. The present invention also relates to a general method of producing novel enveloped viral system which allow to deliver of a a gene of interest to a target cell. The present invention also concerns the use of a protein DC-SIGNs at the surface of an enveloped viral system such as a retrovirus, particularly HIV, for improving the infectivity and/or the titer of said enveloped viral system. The present invention further relates to the use of such envelope system of the present invention for the preparation of a pharmaceutical composition for the treatment of virus infection or pathologies induced by viral infection, particularly HIV infection.
|
